We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EPD:NYSEEnterprise Products Partners L.P. Analysis

Data as of 2026-06-18 - not real-time

$36.78

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Enterprise Products Partners trades at $36.78, sitting just above its 200‑day SMA of $34.49 but below the 20‑day ($37.61) and 50‑day ($37.88) averages, indicating short‑term weakness. The 14‑day RSI of 41 and a bearish MACD histogram reinforce a neutral‑to‑downward bias. Volume has been shrinking, and the 30‑day volatility of nearly 20% suggests price swings remain sizable. The stock’s beta is slightly negative in the model (‑0.12) and modest in the quote (0.47), implying limited correlation with broader market moves. Support sits near $35.98, while resistance is around $39.74, giving a technical upside of roughly 12% to the target price. On the balance sheet, debt‑to‑equity is high at 113%, but operating cash flow exceeds $7.7 bn, and free cash flow, though modest at $156 m, still covers the 80.6% dividend payout.
Fundamentally, EPD’s trailing P/E of 13.6 is well below the oil‑&‑gas midstream peer average of 20, flagging undervaluation. Adjusted EBITDA grew 10% in the latest quarter, and the company raised its quarterly dividend to $2.19, delivering a 6% yield. The fee‑based model, anchored by long‑term contracts, cushions earnings from commodity price swings. Analysts (20) rate the stock a “buy” with a mean target of $41, implying ~12% upside. The forward P/E of 11.7 and a blended growth‑value profile support a long‑run case for ownership. Combined with low market beta and a strong dividend, the fundamentals outweigh the near‑term technical softness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume
  • Price near technical support
  • High dividend yield provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 10% EBITDA growth and dividend increase
  • Analyst target price $41 implying ~12% upside
  • Stable fee‑based cash flow from long‑term contracts

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Undervalued relative to sector P/E
  • Low beta and defensive business model
  • Sustainable high dividend yield

Key Metrics & Analysis

Financial Health

Revenue Growth-6.70%
Profit Margin11.45%
P/E Ratio13.6
ROE19.82%
ROA5.69%
Debt/Equity113.13
P/B Ratio2.7
Op. Cash Flow$7.7B
Free Cash Flow$155.9M
Industry P/E20.0

Technical Analysis

TrendNeutral
RSI41.2
Support$35.98
Resistance$39.74
MA 20$37.61
MA 50$37.88
MA 200$34.49
MACDBearish
VolumeDecreasing
Fear & Greed Index90.86

Valuation

Target Price$41.25
Upside/Downside12.15%
GradeUndervalued
TypeBlend
Dividend Yield6.01%

Risk Assessment

Beta-0.12
Volatility19.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.